ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has earned a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $4.60.

A number of equities analysts have commented on ALXO shares. Wall Street Zen raised ALX Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of ALX Oncology in a report on Friday, June 26th.

ALX Oncology Stock Down 0.5%

Shares of ALXO opened at $2.02 on Tuesday. The stock has a market cap of $271.82 million, a price-to-earnings ratio of -1.36 and a beta of 0.42. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.02. ALX Oncology has a 12 month low of $0.51 and a 12 month high of $2.66. The company has a 50-day moving average price of $1.88 and a two-hundred day moving average price of $1.89.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Equities analysts predict that ALX Oncology will post -0.66 EPS for the current fiscal year.

Institutional Trading of ALX Oncology

A number of large investors have recently made changes to their positions in ALXO. Redmile Group LLC raised its holdings in ALX Oncology by 143.9% during the first quarter. Redmile Group LLC now owns 7,964,188 shares of the company’s stock worth $15,968,000 after acquiring an additional 4,699,470 shares in the last quarter. Vivo Capital LLC bought a new stake in shares of ALX Oncology in the 1st quarter valued at about $6,385,000. venBio Partners LLC increased its position in ALX Oncology by 32.8% during the first quarter. venBio Partners LLC now owns 12,884,638 shares of the company’s stock worth $25,834,000 after buying an additional 3,184,713 shares during the last quarter. Orbimed Advisors LLC bought a new stake in ALX Oncology in the first quarter valued at approximately $5,747,000. Finally, Ameriprise Financial Inc. bought a new stake in ALX Oncology in the 3rd quarter valued at $1,195,000. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.